Prevention or mitigation of t-cell engaging agent-related adverse effects
AssigneeHoffmann-La Roche Inc.
InventorsGabrielle LECLERCQ-COHEN, Johannes SAM, Nathalie STEINHOFF, Pablo UMAÑA
Life of this patent
Estimating the term…
Abstract
The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of NACHT, LRR and PYD domains-containing protein 3 (NLRP3).
Claims35
-2. (canceled)
A method for treatment of a disease in an individual, wherein said method comprises
- (a) the administration of a T cell engaging agent to the individual, and
- (b) the administration of an NLRP3 inhibitor to the individual.
-6. (canceled)
A method for preventing or mitigating an adverse effect related to the administration of a T cell engaging agent to an individual, comprising the administration of an NLRP3 inhibitor to the individual.
Dependencies are inferred from the claim text.